Literature DB >> 12576462

Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation.

Behnam Badie1, Jill M Schartner, Aaron R Hagar, Sakthivel Prabakaran, Todd R Peebles, Becky Bartley, Samir Lapsiwala, Daniel K Resnick, Jessica Vorpahl.   

Abstract

PURPOSE: Cerebral edema is responsible for significant morbidity and mortality in patients harboring malignant gliomas. To examine the role of inflammatory cells in brain edema formation, we studied the expression cyclooxygenase (COX)-2, a key enzyme in arachidonic acid metabolism, by microglia in the C6 rodent glioma model. EXPERIMENTAL
DESIGN: The expression of COX-2 in primary microglia cultures obtained from intracranial rat C6 gliomas was examined using reverse transcription-PCR, Western analysis, and prostaglandin E(2) (PGE(2)) enzyme immunoassay. Blood-tumor barrier permeability was studied in the same tumor model using magnetic resonance imaging.
RESULTS: In contrast to C6 glioma cells, microglia isolated from intracranial C6 tumors produced high levels of PGE(2) through a COX-2-dependent pathway. To test whether the observed microglia COX-2 activity played a role in brain edema formation in gliomas, tumor-bearing rats were treated with rofecoxib, a selective COX-2 inhibitor. Rofecoxib was as effective as dexamethasone in decreasing the diffusion of contrast material into the brain parenchyma (P = 0.01, rofecoxib versus control animals), suggesting a reduction in blood-tumor barrier permeability.
CONCLUSIONS: These findings suggest that glioma-infiltrating microglia are a major source of PGE(2) production through the COX-2 pathway and support the use of COX-2 inhibitors as possible alternatives to glucocorticoids in the treatment of peritumoral edema in patients with malignant brain tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576462

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

Review 1.  Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review.

Authors:  Onder Onguru; Mary B Casey; Sabine Kajita; Nobuki Nakamura; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 2.  What has inflammation to do with traumatic brain injury?

Authors:  David Cederberg; Peter Siesjö
Journal:  Childs Nerv Syst       Date:  2009-11-26       Impact factor: 1.475

3.  Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme.

Authors:  Peter Sminia; T Rianne Stoter; Paul van der Valk; Paula H M Elkhuizen; Thea M Tadema; Gitta K Kuipers; W Peter Vandertop; M Vincent M Lafleur; Ben J Slotman
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

Review 4.  Targeted molecular therapy of malignant gliomas.

Authors:  Santosh Kesari; Naren Ramakrishna; Claire Sauvageot; Charles D Stiles; Patrick Y Wen
Journal:  Curr Neurol Neurosci Rep       Date:  2005-05       Impact factor: 5.081

5.  Radiomic features from the peritumoral brain parenchyma on treatment-naïve multi-parametric MR imaging predict long versus short-term survival in glioblastoma multiforme: Preliminary findings.

Authors:  Prateek Prasanna; Jay Patel; Sasan Partovi; Anant Madabhushi; Pallavi Tiwari
Journal:  Eur Radiol       Date:  2016-10-24       Impact factor: 5.315

6.  Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience.

Authors:  Johannes E Wolff; Michael E Rytting; Tribhawan S Vats; Peter E Zage; Joann L Ater; Shiao Woo; John Kuttesch; Leena Ketonen; Anita Mahajan
Journal:  J Neurooncol       Date:  2011-08-20       Impact factor: 4.130

Review 7.  Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data.

Authors:  Mona Abdel-Tawab; Oliver Werz; Manfred Schubert-Zsilavecz
Journal:  Clin Pharmacokinet       Date:  2011-06       Impact factor: 6.447

Review 8.  Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Authors:  Nikhil G Thaker; Ian F Pollack
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

9.  Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma.

Authors:  S G Temel; Z Kahveci
Journal:  J Mol Histol       Date:  2010-01-06       Impact factor: 2.611

10.  Targeted molecular therapy of malignant gliomas.

Authors:  Santosh Kesari; Naren Ramakrishna; Claire Sauvageot; Charles D Stiles; Patrick Y Wen
Journal:  Curr Oncol Rep       Date:  2006-01       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.